嘉亨家化(300955.SZ):子公司湖州嘉亨取得《化粧品生產許可證》
格隆匯3月9日丨嘉亨家化(300955.SZ)公佈,公司全資子公司湖州嘉亨實業有限公司(簡稱“湖州嘉亨”)於近日收到浙江省藥品監督管理局頒發的《化粧品生產許可證》。生產許可項目為一般液態單元#;膏霜乳液單元#(標註#號的生產許可項目具備兒童護膚類、眼部護膚類化粧品生產條件);有效期至2027年3月8日。
湖州嘉亨此次取得《化粧品生產許可證》後即可依法開展相關業務活動,為湖州嘉亨產品進行商業化生產提供了資質保障;有利於公司實現相關產品的產能擴大,保持穩定的生產能力和產品質量;有利於公司化粧品業務的穩健增長和可持續發展以及公司戰略佈局實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.